Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Conclusion Equivalence for efficacy was demonstrated between SB3 and TRZ on the basis of the ratio of bpCR rates. Safety and immunogenicity were comparable. PMID: 29373094 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research

Related Links:

Conclusion ABVS showed ‘good’ correlation with MRI tumour response evaluation in breast cancer patients during NAC with ‘excellent’ inter- and intra-observer agreement. ABVS has patients’ preference over breast MRI and could be considered as alternative to breast MRI, in case results on an on-going prospective trial confirm these results (NTR6799).
Source: European Journal of Radiology - Category: Radiology Source Type: research
M árcio Debiasi, Carisi A. Polanczyk, Patrícia Ziegelmann, Carlos Barrios, Hongyuan Cao, James J. Dignam, Paul Goss, Brittany Bychkovsky, Dianne M. Finkelstein, Rodrigo S. Guindalini, Paulo Filho, Caroline Albuquerque, Tomás Reinert, Evandro de Azambuja, Olufunmilayo Olopade
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: June 2018 Source:The Kaohsiung Journal of Medical Sciences, Volume 34, Issue 6 Author(s): Dong Hui Cho, Soo Youn Bae, Ji Young You, Hong Kyu Kim, Young Woo Chang, Yoo Jin Choi, Sang Uk Woo, Gil Soo Son, Jae Bok Lee, Jeoung Won Bae, Seung Pil Jung Axillary nodal status is one of the most important prognostic factors in breast cancer. The lymph node ratio (LNR) has been suggested as an independent prognostic factor because the number of dissected and involved lymph nodes might differ across institutions. Neoadjuvant chemotherapy (NAC) has been the preferred treatment method for reducing tumor mass in the b...
Source: The Kaohsiung Journal of Medical Sciences - Category: Universities & Medical Training Source Type: research
In conclusion, we identified no SNPs significantly associated with NAC. The observation, in a hypothesis-generating GWAS, of an SNP in CDKAL1 associated with pCR in the bevacizumab arm of both B-40 and GeparQuinto requires further validation and study.
Source: Pharmacogenetics and Genomics - Category: Genetics & Stem Cells Tags: Short Communication Source Type: research
Authors: Ma G, Huang H, Li M, Li L, Kong P, Zhu Y, Xia T, Wang S Abstract Neoadjuvant chemotherapy (NCT) is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) is commonly used as a valid predictor of NCT long-term outcomes. Blood-based tumor biomarkers have the potential to predict response to NCT at early stage non-invasively. We believed plasma CCL5 could be a potential marker to predict NCT of LABC. Its efficiency and possible mechanism was studied in this work. Human Cytokine Antibody Microarray was applied to screen different cytokine concentration in plasma ...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
ConclusionOur results confirm the possible role of theLAPTM4B gene in anthracycline resistance in HR − breast cancer. AnalyzingLAPTM4B copy number pattern may support future treatment decision.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Authors: Li J, Gao W, Yu B, Wang F, Wang L Abstract PURPOSE: To investigate multi-slice spiral CT (MSCT) imaging with breast cancer chemotherapy and the correlation between MSCT and breast cancer-specific gene 1 (BCSG1). METHODS: 86 patients with breast cancer were enrolled from January 2016 to May 2017. All of them were treated with neoadjuvant chemotherapy, and underwent MSCT scan before and after treatment to evaluate the efficacy of chemotherapy. The expression of BCSG1 in tumor tissue was detected by immunohistochemistry and the correlation between CT results and BCSG1 was analyzed. RESULTS: MSCT evalu...
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
When a patient has a confirmed diagnosis of invasive breast cancer, the patient may receive chemotherapy ahead of surgery. This is called neoadjuvant therapy and is used to shrink tumors before they are removed surgically. It also treats cancer that has spread (metastasized). Imaging tests before and during neoadjuvant treatment can help guide treatment decisions.
Source: Journal of the American College of Radiology : JACR - Category: Radiology Authors: Tags: Appropriate use criteria Source Type: research
CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated. PMID: 29744672 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Drug Investig Source Type: research
ConclusionPLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Taxotere